Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Nivolumab and Pembrolizumab As Immune-Modulating Monoclonal Antibodies Targeting the Pd-1 Receptor to Treat Melanoma Publisher Pubmed



Faghfuri E1 ; Faramarzi MA1 ; Nikfar S2 ; Abdollahi M3, 4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Pharmaceutical Biotechnology and Biotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Toxicology and Pharmacology, Faculty of Pharmacy, Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, 1417614411, Iran
  4. 4. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

Source: Expert Review of Anticancer Therapy Published:2015


Abstract

Malignant melanoma is an important issue in oncology due to its high incidence, high mortality, and resistance to systemic therapy; however, targeted immunotherapy has noticeably improved the survival rates of melanoma patients. Promising targeted immunotherapies for malignant melanoma include the blockade of immune checkpoints with antibodies targeting cytotoxic T lymphocyte-associated antigen 4 and the programmed cell death protein 1 pathway. The US FDA-approved antibody ipilimumab targets cytotoxic T lymphocyte-associated antigen 4; however, it was limited by toxicity and a low response. Nivolumab and pembrolizumab (formerly lambrolizumab), the two FDA-approved anti-programmed death-1 monoclonal antibodies, show highly durable response rates and long-term safety, validating the importance of the programmed cell death protein 1 pathway blockade for treatment of malignant melanoma. © 2015 Informa UK, Ltd.
Related Docs
View other Related Docs
1. Pd-1 and Cancer: Molecular Mechanisms and Polymorphisms, Immunogenetics (2018)
2. Immunotherapy of Cancers Comes of Age, Expert Review of Clinical Immunology (2017)
3. Immune Checkpoint Blockade in Melanoma: Advantages, Shortcomings and Emerging Roles of the Nanoparticles, International Immunopharmacology (2022)
4. The Promising Role of Monoclonal Antibodies for Gastric Cancer Treatment, Immunotherapy (2019)
5. Targeting the Pd-1/Pd-L1 Pathway in Glioblastoma Multiforme: Preclinical Evidence and Clinical Interventions, International Immunopharmacology (2021)
6. Immune Checkpoints and Graves’ Disease, Thyroid Eye Disease, and Orbital Myopathy: A Comprehensive Review, Journal of Ophthalmic and Vision Research (2024)
7. Immune Therapy of Melanoma: Overview of Therapeutic Vaccines, Journal of Cellular Physiology (2019)
8. Exhaustion of T Lymphocytes in the Tumor Microenvironment: Significance and Effective Mechanisms, Cellular Immunology (2017)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (13)
Mohammad Abdollahi (2)
Other Related Docs
9. Immune Checkpoint Inhibitor (Ici) Therapy in Central Nervous System Cancers: State-Of-The-Art and Future Outlook, International Immunopharmacology (2025)
10. Tumor Immunology, Clinical Immunology (2022)
11. Tumor Immunotherapies by Immune Checkpoint Inhibitors (Icis); the Pros and Cons, Cell Communication and Signaling (2022)
12. Chimeric Antigen Receptor T-Cell Therapy for Melanoma, Expert Review of Clinical Immunology (2021)
13. Biomarkers for Predicting the Outcome of Various Cancer Immunotherapies, Critical Reviews in Oncology/Hematology (2021)
14. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
15. Review of the Recent Clinical Trials for Pd-1/Pd-L1 Based Lung Cancer Immunotherapy, Expert Review of Anticancer Therapy (2021)
16. The Potential of T Cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Designing Novel Immunotherapy for Bladder Cancer, Endocrine# Metabolic and Immune Disorders - Drug Targets (2021)
17. The Applications of Anti-Cd20 Antibodies to Treat Various B Cells Disorders, Biomedicine and Pharmacotherapy (2019)
18. Recent Advances on Immune Targeted Therapy of Colorectal Cancer Using Bi-Specific Antibodies and Therapeutic Vaccines, Biological Procedures Online (2021)
19. Pd-1/Pd-L1 Pathway: Basic Biology and Role in Cancer Immunotherapy, Journal of Cellular Physiology (2019)
20. Prognostic Value of 2-[18F]Fdg Pet-Ct in Metastatic Melanoma Patients Receiving Immunotherapy, European Journal of Radiology (2022)
21. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
22. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
23. Anti-Pd-1/Pd-L1 Inhibitor Therapy for Melanoma Brain Metastases: A Systematic Review and Meta-Analysis, Neurosurgical Review (2024)
24. Immune Checkpoint Inhibitors in Advanced Cutaneous Melanoma: A Systematic Review and Meta-Analysis of Efficacy and Review of Characteristics, Expert Review of Anticancer Therapy (2023)
25. Recent Progress in Cancer Immunotherapy: Overview of Current Status and Challenges, Pathology Research and Practice (2023)
26. Immune Checkpoint Inhibitors in Cancer Therapy, Current Oncology (2022)
27. Stat3 Targeting by Polyphenols: Novel Therapeutic Strategy for Melanoma, BioFactors (2017)
28. Shedding Light on the Side Effects of Immunotherapies Used for Leukemia: An Updated Review of the Literature, Expert Review of Anticancer Therapy (2023)
29. Prevalence of Braf V600e and Nras (G12v, G13v) Mutations in Iranian Patients With Melanoma and Their Association With Tumor-Related Factors, Iranian Journal of Dermatology (2024)
30. Nanoparticulate Systems for Combination Therapies of Lung Cancer: A Review, Journal of Nanoparticle Research (2025)
31. Mesenchymal Stromal Cells in Bone Marrow Niche of Patients With Multiple Myeloma: A Double-Edged Sword, Cancer Cell International (2025)
32. Immunotherapy a New Hope for Cancer Treatment: A Review, Pakistan Journal of Biological Sciences (2018)
33. Current and Future Perspectives of Pd-1/Pdl-1 Blockade in Cancer Immunotherapy, Journal of Immunology Research (2021)
34. Applications of Innovation Technologies for Personalized Cancer Medicine: Stem Cells and Gene-Editing Tools, ACS Pharmacology and Translational Science (2023)
35. Resistance to Immunotherapy in Human Malignancies: Mechanisms, Research Progresses, Challenges, and Opportunities, Journal of Cellular Physiology (2022)
36. Mitogen-Activated Protein Kinase (Mek) Inhibitors to Treat Melanoma Alone or in Combination With Other Kinase Inhibitors, Expert Opinion on Drug Metabolism and Toxicology (2018)
37. Expression of Pd1 and Pdl1 As Immune-Checkpoint Inhibitors in Mantle Cell Lymphoma, BMC Cancer (2022)
38. The Roles of Cd4+ T-Cells in Tumor Immunity, Cancer Immunology: A Translational Medicine Context# Second Edition (2020)
39. Immune Checkpoint Inhibitors and Cardiotoxicity: Possible Mechanisms, Manifestations, Diagnosis and Management, Expert Review of Anticancer Therapy (2021)